Copyright
©The Author(s) 2015.
World J Gastroenterol. Oct 14, 2015; 21(38): 10760-10775
Published online Oct 14, 2015. doi: 10.3748/wjg.v21.i38.10760
Published online Oct 14, 2015. doi: 10.3748/wjg.v21.i38.10760
Ref. | Trial | Population | Drug | Overall SVR12 | SVR12 in cirrhosis |
Jacobson et al[143], 2014 | Fusion | G2, G3 experienced | SOF/RBV 12 vs 16 wk | G2 86% vs 94% | G2 60% vs 78% |
34% cirrhotic | G3 62% vs 30% | G3 19% vs 61% | |||
Lawitz et al[33], 2015 | Fission | G2, G3 naïve | SOF/RBV 12 wk vs Peg-IFN/RBV 24 wk | G2 97% vs 78% | G2 92% vs 62% |
20% cirrhosis | G3 56% vs 63% | G3 30% vs 34% | |||
Jacobson et al[143], 2014 | Positron | G2, G3 naïve and experienced IFN ineligible | SOF/RBV | G2 93%, G3 61% | G2 92%, G3 21% |
Zeuzem et al[144], 2014 | Valence | G3 extended 24 wk 21% cirrhosis | SOF/RBV | G2 94%, G3 91% | G2 82%, G3 68% |
Lawitz et al[42], 2015 | Lonestar-2 | G 2 and 3 | SOF/RBV/Peg-IFN | G2 96%, G3 83% | G2 93%, G3 83% |
Bourliere et al[43], 2015 | Sirius | G1 with compensated cirrhosis, NR previous treatment | SOF/LDV 24 wk vs SOF/LDV/RBV 12 wk | N/A | 97% vs 96% |
Lawitz et al[36], 2014 | Cosmos | G1 NR, 52% F3-F4 | SOF/SMV ± RBV 12 or 24 wk | 92% | 94% |
Gane et al[114], 2014 | Electron II | G1 naïve, experienced and decompensated, G3 naïve, 15% cirrhosis | LDV/RBV 12 wk | G1 100%, G3 64% | G1 65% |
- Citation: Righi E, Londero A, Carnelutti A, Baccarani U, Bassetti M. Impact of new treatment options for hepatitis C virus infection in liver transplantation. World J Gastroenterol 2015; 21(38): 10760-10775
- URL: https://www.wjgnet.com/1007-9327/full/v21/i38/10760.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i38.10760